Trials / Completed
CompletedNCT00645814
Multicenter Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severe Chronic Plaque Psoriasis
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 148 (actual)
- Sponsor
- Abbott · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Study of the Safety and Efficacy of Adalimumab in Subjects with Moderate to Severe Chronic Plaque Psoriasis
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | placebo for adalimumab | 80 mg at Week 0 and 40 mg eow through Week 11 |
| DRUG | adalimumab | 80 mg at Week 0 and 40 mg eow through Week 11 |
| DRUG | adalimumab | 80 mg at Week 0 and 40 mg weekly through Week 11 |
Timeline
- Start date
- 2003-03-01
- Primary completion
- 2003-09-01
- First posted
- 2008-03-28
- Last updated
- 2008-03-28
Source: ClinicalTrials.gov record NCT00645814. Inclusion in this directory is not an endorsement.